论文部分内容阅读
目的探讨非小细胞肺癌胸腔积液患者应用胸腔循环热灌注化疗治疗的临床效果及安全性。方法非小细胞肺癌胸腔积液患者80例,随机分为观察组和对照组各40例。观察组应用顺铂40mg/m~2+生理盐水2 000mL行胸腔循环热灌注化疗,对照组应用顺铂40mg/m~2+生理盐水2 000mL行常温胸腔循环灌注化疗,2组治疗均每次1h,每周1次,连续治疗3周。治疗结束后1个月评定2组治疗效果,观察不良反应发生情况。结果治疗结束后1个月,观察组总有效率(87.50%)高于对照组(65.00%)(P<0.05);治疗期间2组不良反应均为Ⅰ~Ⅱ级,经对症治疗均可缓解,观察组消化道反应、胸痛及骨髓抑制发生率(25.0%、25.0%、30.0%)与对照组(35.0%、17.5%、37.5%)比较差异均无统计学意义(P>0.05)。结论胸腔循环热灌注化疗治疗非小细胞肺癌胸腔积液疗效确切,安全性较好。
Objective To investigate the clinical effect and safety of thoracic thermal perfusion chemotherapy in patients with pleural effusion of non-small cell lung cancer. Methods 80 patients with pleural effusion of non-small cell lung cancer were randomly divided into observation group and control group, 40 cases each. In the observation group, cisplatin 40 mg / m 2 + normal saline 2 000 mL was used in the treatment of thoracic circulation. The control group was treated with cisplatin 40 mg / m 2 + normal saline 2 000 mL at room temperature. 1h, once a week for 3 weeks. One month after the end of treatment, the curative effect of two groups was evaluated and the occurrence of adverse reactions was observed. Results The total effective rate (87.50%) in the observation group was significantly higher than that in the control group (65.00%) at 1 month after the treatment (P <0.05). The adverse reactions of the two groups were grade Ⅰ ~ Ⅱ during the treatment period, The incidences of digestive tract reaction, chest pain and bone marrow suppression (25.0%, 25.0%, 30.0%) in the observation group were not significantly different from those in the control group (35.0%, 17.5%, 37.5%) (P> 0.05). Conclusion Intrathoracic thermal perfusion chemotherapy for the treatment of pleural effusion of non-small cell lung cancer is effective and safe.